Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine Salvage Therapy in Pediatric Refractory/Relapsed Langerhans Cell Histiocytosis
ChiCTR2500102536Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clofarabine in Langerhans cell histiocytosis (LCH), sponsored by Beijing Children's Hospital. Primary endpoint: 2-year event-free survival rate. Started May 2025; status: recruiting.
02
Drugs
clofarabine
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2500102536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102536.